Stevanato Group SpA (STVN) FinancialsSTVNFinancialStevanato Group SpA

Stevanato Group SpA (STVN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Revenues from high-value solutions, accounting for 45.0% of total sales, equivalent to €135.93M. Other significant revenue streams include Revenues from other containment and delivery solutions and Revenues from engineering. Understanding this composition is critical for investors evaluating how STVN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Stevanato Group SpA maintains a gross margin of 29.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 18.04%, while the net margin is 7.60%. These profitability ratios, combined with a Return on Equity (ROE) of 9.13%, provide a clear picture of how effectively STVN converts its operational activities into shareholder value.

In the context of the broader market, STVN competes directly with industry leaders such as MMED and TFX. With a market capitalization of $5.75B, it holds a significant position in the sector. When comparing efficiency, STVN's gross margin of 29.51% stands against MMED's 57.35% and TFX's 58.16%. Such benchmarking helps identify whether Stevanato Group SpA is trading at a premium or discount relative to its financial performance.

Stevanato Group reported a Q2 2026 revenue of €302 million, a 7.9% year-over-year growth, and a gross margin of 28.7%, which is an improvement of 60 basis points year-over-year. The adjusted EBITDA margin also increased to 26.0%, showcasing operational efficiency.